Perfusion CT Imaging in Lung Cancer With SBRT

Lung Cancer Clinical Trial

Official title:

Perfusion CT Imaging in Patients With Lung Malignancies Receiving Stereotactic Body Radiation Therapy (SBRT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02755454
• Other study ID #: 12-5386-CE
• Status: Completed
• Phase: N/A
• Start date: October 2013
• Est. completion date: November 20, 2018

Study information

• Verified date: November 2018
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine specific perfusion patterns for radiation induced lung changes and residual/recurrent lung malignancies in patients treated with stereotactic body radiotherapy SBRT and thus improve to distinguish radiation changes from residual/recurrent lung cancers. Currently CT is often unable to make a clear differentiation between benign and malignant changes in the lung after SBRT treatment necessitating additional wait time to perform follow up CTs or biopsies. Optimal treatment may be delayed. The investigators want to apply a CT perfusion sequence in addition to the routine follow up CTs with the goal to obtain perfusion values of post treatment lung changes and lung tumours. The investigators' hypothesis is that CT perfusion values will help differentiate benign post radiation changes from residual/recurrent tumour in the lung with higher confidence and may help avoid unnecessary delays in cancer treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: November 20, 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Gender: male or female

• CT ordered for baseline and follow up in patients with lung cancer and lung metastases treated with

• Patient will sign a consent form prior to study entry

• Lung cancer and lung metastases are biopsy proven

Exclusion Criteria:

• Patients who are unable to give valid informed consent

• Patients who are unwilling or unable to undergo a CT exam, including subjects with contra-indications to CT exams or intravenous contrast material administration.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• Perfusion CT Imaging

Locations

Country	Name	City	State
Canada	Patrik Rogalla	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Imaging of during and after SBRT treatment for lung malignancies with a combined perfusion and routine CT to assess therapy response of lung cancer and metastases.		3-6 months